ClinicalTrials.gg
RecruitingNCT06740019Updated Apr 4, 2025

A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

A Phase 1 interventional study of JMKX000197 and Tube thoracostomy drainage in Malignant Pleural Effusions (Mpe), sponsored by Jemincare. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 10 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

02

Conditions studied

  • Malignant Pleural Effusions (Mpe)
03

In context

Pleural Effusion, Malignant

169 studies on the registry are indexed under Pleural Effusion, Malignant; 39 are open to participants now.

This study's planned enrollment of 30 is below the median of 55 across 125 interventional studies indexed under Pleural Effusion, Malignant.

Browse Pleural Effusion, Malignant studies →

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant voluntarily joined the study, signed an form, and had good compliance.
  2. Age ≥ 18 years and ≤ 75 years old, regardless of gender.
  3. Participants with advanced solid tumors diagnosed by histopathology or cytopathology.
  4. Malignant pleural effusion confirmed by histopathology or cytopathology or clinically diagnosed as moderate or above and requiring drainage.
  5. (ECOG) performance status: 0 to 2.
  6. of at least 3 months.
  7. Adequate organ function.
  8. Female participants of should agree to use to prevent pregnancy until 6 months after discontinuation of JMKX000197. The serum pregnancy test result should be negative 7 days before enrollment and must be a non-lactating participant. Male participants must agree to use effective contraception during the study and for 6 months after discontinuation of JMKX000197.

Exclusion criteria

Exclusion Criteria:

  1. Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.
  2. Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.
  3. Have used interferon gene stimulating factor (STING) agonists for pleural perfusion。
  4. Known allergies to the study drug or its components.
  5. Have participated in other clinical trials within 28 days prior to randomization.
  6. Major surgery within 28 days prior to randomization.
  7. Central nervous system disease, , or cord compression.
  8. Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.
  9. Uncontrollable systemic infections (viruses, bacteria, fungi), including but not limited to positive and HBV DNA, positive , positive antibody test or combined infections within the first 28 days of randomization and require systemic anti-infective treatment.
  10. Have a history of organ transplantation.
  11. Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Arm A

    JMKX000197 Dose 1

    Drug: JMKX000197

  • Experimental
    Arm B

    JMKX000197 Dose 2

    Drug: JMKX000197

  • Other
    Arm C

    Tube thoracostomy drainage

    Procedure: Tube thoracostomy drainage

Interventions

  • for pleural perfusion

  • ProcedureTube thoracostomy drainage

    Tube thoracostomy drainage

06

What researchers measure

Primary outcomes

  1. AEs or SAEs

    Time frame: Up to approximately 36 days

  2. Recommended Phase II dose (RP2D)

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Puncture /drainage-Free Survival (PuFS)

    Time frame: Up to approximately 24 months

  2. Pleural effusion overall response (ORR)

    Time frame: Up to approximately 24 months

  3. Overall survival (OS)

    Time frame: Up to approximately 24 months

  4. Pharmacokinetics (Cmax)

    Time frame: Up to approximately 7 days

  5. Pharmacokinetics(Tmax)

    Time frame: Up to approximately 7 days

  6. Pharmacokinetics (t1/2)

    Time frame: Up to approximately 7 days

  7. Pharmacokinetics (AUC0-inf)

    Time frame: Up to approximately 7 days

  8. Pharmacokinetics (AUC0-t)

    Time frame: Up to approximately 7 days

  9. Amount of Drug Excreted Via Urine and Excrement

    Time frame: Up to approximately 48 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06740019
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Dec 28, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 4, 2025

Study contacts

Fawei Wu
Contact
wufawei@jemincare.com
+86 15720614080
Ning Li
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JMKX000197

Start the discussion